ADAM17 and hypertensive disorder: In an interesting study using a mouse model of Ang-II-induced hypertension without smooth muscle ADAM17 participation, caused by gen deletion or systemic pharmacological inhibition of ADAM17, the vascular hypertrophy and perivascular fibrosis were reduced (Takayanagi et al., 2016).